A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
about
Mepolizumab versus placebo for asthmaA review of omalizumab for the management of severe asthmaPharmacotherapy in the management of asthma in the elderly: a review of clinical studiesPathophysiology of chronic rhinosinusitis, pharmaceutical therapy optionsDefining severe asthma - an approach to find new therapiesSevere asthma: anti-IgE or anti-IL-5?Biologics in asthma--the next step toward personalized treatmentTargeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Relevance of allergy in adult asthma.Novel diagnostic approaches and biological therapeutics for intrinsic asthma.Against all odds: anti-IgE for intrinsic asthma?Omalizumab, an anti-immunoglobulin E antibody: state of the art.Bronchial asthma: is personalized therapy on the horizon?Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanismsIgE mediated sensitisation to aeroallergens in an asthmatic cohort: relationship with inflammatory phenotypes and disease severity.IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Omalizumab: a review of its use in patients with severe persistent allergic asthma.Omalizumab for severe asthma: efficacy beyond the atopic patient?Critical review of bronchial thermoplasty: where should it fit into asthma therapy?Off-Label Uses of Omalizumab.Omalizumab therapy for children and adolescents with severe allergic asthma.Treatment of severe asthma: entering the era of targeted therapy.Omalizumab in non-allergic asthma: A report of 13 cases.Can biomarkers help us hit targets in difficult-to-treat asthma?Targeted therapeutics for severe refractory asthma: monoclonal antibodies.Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis.New insights into basophil heterogeneity.Nonallergic rhinitis and lower airway disease.Novel monoclonal treatments in severe asthma.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies.Prospects for new and emerging therapeutics in severe asthma: the role of biologics.Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.A Practical Approach to Severe Asthma in Children.Anti-IL5 therapies for asthma.Biologic agents for severe asthma patients: clinical perspectives and implications.An update on the management of aspirin-exacerbated respiratory disease.New approaches for identifying and testing potential new anti-asthma agents.Airway basophils are increased and activated in eosinophilic asthma.Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
P2860
Q24186306-5AAC6FD6-B5A6-4F35-99C9-769BF0178295Q26741315-36C388FE-D6CE-4A0F-91A7-271524B9E6AEQ26769046-4885C5D5-22D1-4994-8039-397E49A0F348Q26771860-4B91FAAB-4F51-4A1E-B008-154F065FBF18Q27001054-3FBC2021-B2E7-4747-ABAE-2B8625F0125EQ28071832-EE0CC575-DE2C-4F4E-B72C-530ECBACF505Q28085614-5BF3967D-EB7F-4E39-A8D4-ACD744077807Q30360362-70385777-2B5C-4ADE-9611-12E3ADBFD101Q33622564-1F12ED38-B9DB-48D8-8074-80C5CF659A51Q33904534-815B88EB-5C88-479D-ABA0-1320220AAFACQ34346950-CFC71585-E639-41D5-8EC4-4D64EB0E3B53Q35095218-B628F78B-E7B0-49D1-8DFF-4F2DE79C21CBQ35777120-53BE78BC-36AD-45EE-A62D-864D0D529B12Q35947771-F0AFA7E8-0AEB-4FF9-B8DF-9EA85195BAF1Q37391767-6E70C704-AD82-46BB-BF61-25D50393E808Q37554168-E716DB34-4074-4019-BD02-C359BB21D4E9Q38118172-F73398D1-6B4F-44F1-B129-8DB6F15D3336Q38201304-61565745-D3BD-4D34-BEA6-2033B66322D7Q38246110-B24198B7-CDC6-4274-B380-3F03948FCDFBQ38517653-278505A9-E154-4D33-B4AD-2DED6044BCC2Q38574776-DE7B6EB6-E058-4D6C-8DBD-5EEED37B04EEQ38578918-81CB49FC-D5B3-45EE-BA60-EABD00A741E7Q38628853-1C9E7DE1-0695-438B-9E88-097CF7C4D4B9Q38752058-62F1D3D1-4851-4812-A5C7-12E2FD3B4061Q38790815-097226A8-106F-4553-9871-5CE80C7CB68EQ38811262-CDD5E814-1255-4994-AF06-160E6CD00BBFQ38834168-FA0F5883-C9FA-4C97-B9F1-881529BF091DQ38903455-79F6F790-3EE9-466E-A186-535140546CEFQ38911706-AA94050D-3C22-463E-B800-0972CA562180Q38982481-5AB0FF01-FAA5-43A0-A54B-807349DF5F49Q39108259-F9763476-D773-4D14-B10B-C7638D8A91A7Q39278773-E17D19DB-7E45-4CF2-B295-A3B0FC0173A5Q39633151-B6B455B6-574F-4B35-9B8E-7C544DB5B5BFQ47197489-37C2975D-E5F2-4016-9251-E453CDBAC897Q47551081-3608C01A-F192-4085-B359-E735303AF827Q47576873-A7D57B3E-410F-44F7-AAC2-DEE6452A6EA1Q47678797-1D7CC986-9CA7-498B-B28B-060E5393334FQ47873103-71C1F17D-BE0B-48AD-A5DC-9ADEE27A0BE2Q47901112-0316CB31-2E5F-4159-B7DA-8FCF6B1EF969Q47921576-04FA8E83-28C5-4FCE-B5F6-8305EE993517
P2860
A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@en
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@nl
type
label
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@en
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@nl
prefLabel
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@en
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@nl
P2093
P356
P1433
P1476
A proof-of-concept, randomized ...... -to-control, nonatopic asthma.
@en
P2093
Alain Didier
Antoine Magnan
Camille Taillé
Cécile Contin-Bordes
Dermot S O'Callaghan
Frédéric de Blay
Gilles Devouassoux
Gilles Garcia
Isabelle Bourdeix
Louis-Jean Couderc
P304
P356
10.1378/CHEST.12-1961
P407
P577
2013-08-01T00:00:00Z